Research results are popular Weight loss drug Known as an GLP-1 agent can help it. More than suppressing appetite -The new research has a potential impact. Cancer risk. GLP-1 drugs include popular brand names such as Ozempic, Wegovy and Zepbound.
In the 2025 observation study published on Thursday before the American Society of Clinical oncology Conference, researchers found that GLP-1 could properly reduce the risk of 14 obese cancers. ColonWhen comparing with other types of drugs that are often used to treat diabetes known as dippeptidil peptida -4 (DDP -4) inhibitors without weight loss effect.
“Patients with GLP-1 receptor agents have a 7% lower risk of obesity-related cancer, and the risk of death due to all causes was 8% lower than that of patients taking DDP-4 inhibitors.”
The study looked at 170,030 adults with obesity and diabetes in 43 health systems in the United States.
The difference between the two treatments was not statistically significant to men, but women who were treated with GLP-1 found that they had a 20% lower risk of all deaths compared to the 8% lower risk of obesity and DDP-4 inhibitors.
The author of this study is National Institute of HealthThe National Institute of Diabetes, Digestive and Kidney disease said that we hope to continue research with people without diabetes for more than four years.
“Seeing a patient with a lot of obesity Cancer and obesityDr. Robin Zon, the president of the US Clinical Oncology, is important to define the clinical role of GLP-1 drugs in cancer prevention. In order to verify these results, including patients without diabetes, future research is required. “
an American Cancer Society ResearchPublished last year CA: Cancer Journal for ClinicIn the United States, more than 40% of all cancer deaths in the United States may be related to the risk of lifestyle that can be changed, including smoking and excessive weight. Alcohol consumptionPhysical activity and diet.
